ClinicalTrials.gg
Not yet recruitingNCT07943403Updated Nov 17, 2026

Food Literacy, Gut Microbiota and Nutritional Status in Adults With Type 2 Diabetes Mellitus

An observational study in Gut Microbiota, Tip 2 Diabetes Mellitus and Food Literacy, sponsored by Istanbul Gedik University. Not yet recruiting. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Istanbul Gedik University · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

This project is a two-phase, observational, cross-sectional study aiming to evaluate the relationships among food literacy, nutritional status, and gut microbiota profile in individuals with type 2 diabetes mellitus (T2DM).

In the first phase of the project, the questionnaire developed by Ludwig et al. (2024) for individuals with T2DM will be adapted into Turkish, and its validity and reliability will be evaluated. In the second phase, the study aims to determine the relationship between the level of food literacy and structural characteristics of the gut microbiota, such as microbial diversity and the Bacillota/Bacteroidota ratio. In addition, potential associations between biomarkers reflecting intestinal barrier integrity and food literacy will be investigated. Furthermore, the relationship between participants' nutritional status and gut microbiota profile will be assessed, differences in microbiota composition across different body mass index (BMI) categories will be examined, and the association between food literacy level and indicators of glycemic control will be determined.

The study will be conducted among volunteer individuals attending the Obesity and Diabetes Outpatient Clinic of the Department of Endocrinology and Metabolism, İstanbul University-Cerrahpaşa Faculty of Medicine. Sociodemographic information, 24-hour dietary records, anthropometric measurements, body composition, physical activity level, routine biochemical parameters, intestinal permeability biomarkers (LPS, zonulin, occludin, and claudin), and stool samples will be collected from the participants. Data collection will be conducted at a single time point, and the findings obtained will be analyzed using appropriate statistical methods.

The originality of the project lies in its holistic approach to food literacy in T2DM management by considering it together with gut microbiota and indicators of metabolic control. In addition, the Turkish adaptation of the food literacy scale developed specifically for individuals with T2DM will contribute to the literature by providing a valid and reliable measurement instrument that can be used in this field.

The findings of the study are expected to contribute to the development of evidence-based intervention programs targeting the behavioral and biological management of T2DM by elucidating the relationships among food literacy level, glycemic control, dietary patterns, and microbial diversity.

02

Conditions studied

  • Gut Microbiota
  • Tip 2 Diabetes Mellitus
  • Food Literacy

Keywords

  • gut microbiota
  • glycemic control
  • type 2 diabetes mellitus
  • nutritional status
03

In context

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's planned enrollment of 60 is below the median of 300 across 1,744 observational studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Istanbul Gedik University is the lead sponsor of 13 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male aged 18-65 with type 2 diabetes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants aged 19-65 years.
  • Clinical diagnosis of Type 2 diabetes mellitus for at least one year.
  • (BMI) between 18.5 and \<40 kg/m².
  • Sufficient cognitive ability to understand the purpose and procedures of the study.
  • Ability to read, write, and communicate in Turkish.
  • Voluntary agreement to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of Type 1 diabetes mellitus.
  • Presence of severe metabolic complications of diabetes, such as diabetic ketoacidosis.
  • Presence of diabetes-related organ complications, such as diabetic nephropathy.
  • Diagnosis of liver or kidney disease.
  • Untreated hypothyroidism.
  • Diagnosis of inflammatory bowel disease or celiac disease, including a positive tissue transglutaminase test.
  • Diagnosis of cancer.
  • Engagement in high-intensity physical exercise.
  • Use of antibiotics, antifungals, probiotics, or prebiotics within the previous three months.
  • Alcohol or substance dependence.
  • Presence of an acute infection at the time of enrollment or a history of serious infection within the previous month.
  • \<18.5 or ≥40 kg/m².
  • Female sex.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • one group

    It is the only type of cross-sectional study that does not involve any intervention.

06

What researchers measure

Primary outcomes

  1. Food Literacy

    The assessment is conducted using the Food Literacy Behaviors Questionnaire for Adults with Type 2 Diabetes (EFLBQ-DB), which has been adapted into Turkish and undergone validity and reliability analyses. The total score ranges from 21 to 84, with higher scores indicating higher levels of food literacy.

    Time frame: 3 months

  2. Gut microbiota profile

    Assessment of gut microbiota composition and diversity using stool samples, including alpha and beta diversity indices, relative abundances of Bacillota and Bacteroidota, and the Bacillota/Bacteroidota ratio where applicable. Associations with food literacy behaviors and nutritional status will be examined. (16S rRNA)

    Time frame: 3 months

  3. Serum markers related to gut barrier function and microbial translocation

    Serum lipopolysaccharide (LPS), zonulin, occludin, and claudin concentrations and their associations with gut microbiota, nutritional status, food literacy behaviors, and metabolic indicators.

    Time frame: 3 months

  4. Glycemic and metabolic indicators

    Fasting blood glucose and fasting insulin concentrations; HOMA-IR may be calculated if appropriate.

    Time frame: 3 months

Secondary outcomes

  1. Anthropometric measurements and body composition

    Body Weight: Body weight will be measured in kilograms (kg). Height: Height will be measured in meters (m). Body Mass Index (BMI): BMI will be calculated as body weight (kg) divided by the square of height (m²) and reported in kg/m². Waist Circumference: Waist circumference will be measured in centimeters (cm). Hip Circumference: Hip circumference will be measured in centimeters (cm). Body Fat Percentage: Body fat percentage will be assessed and reported as a percentage (%). Muscle Mass: Muscle mass will be assessed and reported in kilograms (kg). Body Water Percentage: Body water percentage will be assessed and reported as a percentage (%).

    Time frame: 3 months

  2. Dietary intake

    Energy and nutrient intake assessed using a 24-hour dietary recall, and their associations with food literacy behaviors, gut microbiota profile, and glycemic indicators.

    Time frame: 3 months

  3. Routine biochemical parameters

    Albumin, total cholesterol, HDL-C, LDL-C, VLDL-C, triglycerides, blood urea, creatinine, uric acid, ALT, AST, GGT, and LDH.

    Time frame: 3 months

  4. Physical activity level

    Assessment of physical activity using the International Physical Activity Questionnaire-Short Form (IPAQ-SF).

    Time frame: 3 months

  5. Sociodemographic and clinical characteristics

    Assessment of participant characteristics and relevant clinical information using a structured participant information form. These variables will be used to describe the study population and identify potential confounders.

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Of 434 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 3 months is below that.

Counting every sponsor, half of 604 studies reached it within 32 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2026
First posted
Nov 17, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Feb 20, 2027
CompletionEst.
Apr 1, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943403
Lead sponsor
Istanbul Gedik University
Collaborators
Gazi University
Responsible party
Zeynep Bostan (Research Assistant, Istanbul Gedik University) — Principal investigator
First posted
Nov 17, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Feb 20, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Zekiye Z Bostan, Research Assistant
Contact
zekiyebatcik@gmail.com
+905052720130

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion